In colon cancer, RSPO2 and RSPO3 gene fusions have been proposed to potentiate Wnt/β‐catenin signaling, providing a mutational alternative for classical APC and CTNNB1 mutations [7]. Here, RSPO3 is linked to colonic neoplasm.